Posted on Leave a comment

Sildenafil may be the Cure for Heart Failures among Men

 
welcome By: Elena Grace Flores
Yes, Sildenafil is the scientific name of Viagra, the medication for men with erectile dysfunction has been tested to be helping men with coronary conditions. However, it is also noted in the report of the studies that they have different effects among women. This is contrary to rumors that Viagra takers can end up suffering from heart attack while under its influence!

Sildenafil, inhibits the enzyme PDE5 depleting cGMP reservoirs – thus, raising the cGMP levels effective in fighting cardiac disease. Blood vessels are dilated by the drug to drive blood into the penis to solve the problem of erection. The same effect is needed to enhance blood flow into a defective heart.

Estrogen clearly showed some effects when exposed to the drug when tested in the laboratory among mice. It is found to be less effective in female mice without ovaries. There is clearly a critical impact between estrogen and Sildenafil. It must be insured that there’s high levels of estrogen in women to acquire the intended results – because the collection of cGMP relies on that and estrogen is a natural heart protector. Whereas in males, no need to have the cGMP pool because the drug is directly synthesized according to the heart damage. So, it is suggested that unless a clinical research addressed the Sildenafil-estrogen issue, it’s safer to just prescribe the drug to males with cardiac damages.

The above details are extracts of the report on the John Hopkins research with Dr. Eiki Takimoto as the head. He stressed that it took them 10 years to conclude their findings because remodeling the cardiac system is compared to restructuring of underlying mechanism. They definitely found the element that prevents stressors and hypertension. This is the cGMP or cyclic guanosine menophosphate which is basically a molecule.

Enhanced by Zemanta
Posted on Leave a comment

Sleeping Pills Intensify Cardiac Conditions

 
welcome By: Elena Grace Flores
It has been a tradition by practitioners to prescribe sleeping pills to the patients with heart problems after discharging them from the hospital – for their intended recovery at home. However, it has been noted also that the more the patients are hospitalized the worst their heart condition become. This triggered researchers to review the prescription of discharged patients – and the focus was brought to sleeping pills since they are the most consistently prescribed drugs.

111 cardiac patients were involved in the testing of the sleeping pill connection with the deteriorating heart ailments. Their records were reviewed after being admitted to Japan’s Tokyo Yamate Medical Center from 2011 to 2013. Electrocardiogram results, echocardiograms analysis and chest radiographs viewings were analyzed. There were 3 group classifications done for the tests. The first group consists of diastolic heart failure patients, next are the ones with reduced ejection fraction and lastly the group of systolic heart failure patients. Fatal cases and frequent hospital readmissions were notable among patients with diastolic heart failure.

There was a trend noticed also among patients. Patients with sleeping pills prescription even up to the latest stage of their ailment suffered at least 8 times re-hospitalization than those whose sleeping pills prescription was discontinued. Others end up dead with the worsened condition. The length of their benzodiazepine hypnotic treatment was measured in the differences of blood sodium levels when admitted and blood hemoglobin levels when discharged.

The findings were assumed to be the effect of Benzodiazepine hypnotics having cardiodepressant actions. Respiratory depressant actions can occur which lead to sleep disordered breathing that is fatal. Dr. Masahiko Setoguchi who led the research team of the Social Insurance Central General Hospital in Tokyo, Japan, clarified that sleeping disorders are side effects of heart failure thus, the reason of sleeping pills prescription. This study was initiated based on the Heart Failure Congress 2014 presentation in Athens, Greece.

Enhanced by Zemanta